辅助糖皮质激素治疗重症社区获得性肺炎的疗效与安全性:随机对照试验的系统评价与Meta分析
该系统评价与Meta分析检索Medline、Embase、ClinicalTrials.gov和Scopus截至2023年4月24日的文献,纳入评估辅助糖皮质激素治疗重症社区获得性肺炎(sCAP)疗效与安全性的随机对照试验(RCT),共纳入7项RCT、1689例患者。主要终点30天全因死亡率在激素组低于对照组(RR 0.61,95%CI 0.44–0.85,p<0.01),异质性低(I²=0%,p=0.42)。激素组需机械通气的风险更低(RR 0.57,95%CI 0.45–0.73,p<0.001),ICU住院时间更短(MD -0.8,95%CI -1.4至-0.1,p=0.02),总住院时间更短(MD -1.1,95%CI -2.0至-0.1,p=0.04)。胃肠道出血、医疗保健相关感染和急性肾损伤在两组间无显著差异。作者结论认为辅助糖皮质激素可提供生存获益并改善临床结局而不增加不良事件,但汇总证据仍不确定,需进一步研究。
要点
- 在sCAP患者中,辅助糖皮质激素组30天全因死亡率低于对照组(RR 0.61,95%CI 0.44–0.85,p<0.01),异质性低(I²=0%,p=0.42)。
- 激素组需机械通气的风险低于对照组(RR 0.57,95%CI 0.45–0.73,p<0.001)。
- 激素组ICU住院时间(MD -0.8,95%CI -1.4至-0.1,p=0.02)和总住院时间(MD -1.1,95%CI -2.0至-0.1,p=0.04)均短于对照组。
- 胃肠道出血(RR 1.03,95%CI 0.49–2.18,p=0.93)、医疗保健相关感染(RR 0.89,95%CI 0.60–1.32,p=0.56)和急性肾损伤(RR 0.68,95%CI 0.21–2.26,p=0.53)在两组间无显著差异。
- 作者结论认为辅助糖皮质激素可提供生存获益并改善临床结局而不增加不良事件,但汇总证据仍不确定,需进一步研究。
适用人群与场景
- 重症社区获得性肺炎(sCAP)患者,纳入评估辅助糖皮质激素疗效与安全性的随机对照试验。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,仅纳入随机对照试验(RCT),共纳入7项RCT、1689例患者。
- 主要终点:30天全因死亡率,激素组低于对照组(RR 0.61,95%CI 0.44–0.85,p<0.01),异质性低(I²=0%,p=0.42)。
- 次要终点:需机械通气风险激素组低于对照组(RR 0.57,95%CI 0.45–0.73,p<0.001);ICU住院时间激素组短于对照组(MD -0.8,95%CI -1.4至-0.1,p=0.02);总住院时间激素组短于对照组(MD -1.1,95%CI -2.0至-0.1,p=0.04)。
- 安全性:胃肠道出血(RR 1.03,95%CI 0.49–2.18,p=0.93)、医疗保健相关感染(RR 0.89,95%CI 0.60–1.32,p=0.56)和急性肾损伤(RR 0.68,95%CI 0.21–2.26,p=0.53)在两组间无显著差异。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析。
- 局限:作者指出汇总证据仍不确定,需进一步研究。
对床旁实践的改变
- 作者结论认为,在sCAP患者中辅助糖皮质激素可提供生存获益并改善临床结局而不增加不良事件,但汇总证据仍不确定,需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: This systematic review and meta-analysis aimed to investigate the clinical efficacy and safety of systemic corticosteroids in the treatment of patients with severe community-acquired pneumonia (sCAP).
METHODS: A comprehensive search was conducted using the Medline, Embase, ClinicalTrials.gov, and Scopus databases for articles published until April 24, 2023. Only randomized controlled trials (RCTs) that assessed the clinical efficacy and safety of adjunctive corticosteroids for treating sCAP were included. The primary outcome was the 30-day all-cause mortality.
RESULTS: A total of severe RCTs involving 1689 patients were included in this study. Overall, the study group had a lower mortality rate at day 30 than the control group (risk ratio [RR], 0.61; 95% CI 0.44 to 0.85; p < 0.01) with low heterogeneity (I2 = 0%, p = 0.42). Compared to the control group, the study group had a lower risk of the requirement of mechanical ventilation (RR 0.57; 95% CI 0.45 to 0.73; p < 0.001), shorter length of intensive care unit (MD - 0.8; 95% CI - 1.4 to - 0.1; p = 0.02), and hospital stay (MD - 1.1; 95% CI - 2.0 to - 0.1; p = 0.04). Finally, no significant difference was observed between the study and the control groups in terms of gastrointestinal tract bleeding (RR 1.03; 95% CI 0.49 to 2.18; p = 0.93), healthcare-associated infection (RR 0.89; 95% CI 0.60 to 1.32; p = 0.56), and acute kidney injury (RR 0.68; 95% CI 0.21 to 2.26; p = 0.53).
CONCLUSIONS: In patients with sCAP, adjunctive corticosteroids can provide survival benefits and improve clinical outcomes without increasing adverse events. However, because the pooled evidence remains inconclusive, further studies are required.
参考来源
- Wu JY, Tsai YW, Hsu WH, et al. Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2023. PMID: 37422686. doi:10.1186/s13054-023-04561-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。